Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Roivant Sciences GmbH. (11/13/18). "Press Release: Roivant Sciences Announces $200 Million Investment Round". Basel & London.

Organisations Organisation Roivant Sciences GmbH
  Group Roivant (Group)
  Organisation 2 RTW Investments L.P.
Products Product pharmaceutical
  Product 2 investment banking
Index term Index term Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments
Person Person Davis, Paul (Roivant 201708 Manager Communications Strategy)

Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors comprise a majority of the round. All existing institutional shareholders in Roivant are also participating. The financing values Roivant at approximately $7 billion.

All investors will continue to hold common equity, without liquidation preferences. The proceeds will be used primarily to launch additional Vants developing innovative medicines and technologies. The round is expected to close by early December.

Since Roivant’s last financing in 2017:

> The number of therapies in development has grown from 14 to 34
> The number of Vants has grown from 6 to 14
> The number of employees across Roivant and the Vants has increased from under 350 to over 750
> Roivant subsidiary Enzyvant initiated a Biologics License Application for a regenerative therapy to the U.S. Food and Drug Administration

Roivant anticipates topline data from six Phase 3 clinical trials and multiple clinical readouts from earlier-stage therapies across its family of companies in 2019, as well as growing revenue at Datavant and other new Vants launched by Roivant Health.

About Roivant Sciences

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization.

For more information, please visit


Paul Davis
Head of Communications

Record changed: 2018-11-16


Picture [iito] Plain Stupid Simple 650x80px

More documents for Roivant (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top